Foster Wheeler completes GSK project in Singapore

Published: 1-Apr-2003


Foster Wheeler, a global company offering design engineering, construction, manufacturing, project development and management, research, plant operation and environmental services, has successfully completed a Production Building 3 (PB3) expansion project in Singapore, on behalf of GlaxoSmithKline (GSK).

The expansion represents an investment of US$45.5m (€42.2m) and comes as a response to increasing demand for GSK's asthma treatment. The project expands PB3, GSK's pharmaceutical bulk manufacturing facility, enabling the company to double production capacity of fluticasone propionate, an active pharmaceutical compound.

Meanwhile, Foster Wheeler, in association with Ishikawajima-Harima Heavy Industry (IHI), has been awarded an €80m ($86m) contract to build a new active pharmaceutical ingredients (API) plant. The facility will be on a 20-acre greenfield site at Grange Castle, Republic of Ireland, and is being built on behalf of Takeda Chemical Industries, Japan's largest pharmaceutical company.

The plant, Takeda's first overseas API plant, will produce the actives for drugs to be used in clinical trials, as well as Actos (pioglitazone hydrochloride), used to treat diabetes. It is expected to be on stream by January 2004. Actos is currently processed by Takeda at its pharmaceutical finishing plant in Bray, County Wicklow, which will complement the facilities at the new plant.

  • Companies:
  • Foster Wheeler AG
See more

You may also like

Regulatory

European Commission approves AMEC takeover of Foster Wheeler

Read more
After deal did not raise competition concerns

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

European Commission approves AMEC takeover of Foster Wheeler

After deal did not raise competition concerns
You need to be a subscriber to read this article.
Click here to find out more.
Design & Build

Looking for more sustainable processes

Moving to more sustainable and productive ways of manufacturing has to be the way forward for an industry facing higher costs and a squeeze on drug pricing. Susan Birks reports
Design & Build

Foster Wheeler acquires Yonkers Industries

Purchase provides a construction management capability in North America
Ingredients

Foster Wheeler to convert Teesside fish oil facility into API plant

Will use fish oil in omega-3 active pharmaceutical ingredient
Design & Build

Closed vial technology

Ready-to-fill syringes are increasingly being adopted by pharma, so what about ready-to-fill vials? Germana Molinari, manager of fill/finish process design in Foster Wheeler’s Milan Pharma division, looks at closed vial technology
Manufacturing

Turn batch to continuous processing

Continuous processing is a future goal for the industry. Process expert Nigel Fletcher, Foster Wheeler, examines the effects of converting a conventional batch process into a continuous one and the benefits that were realised once in production

Foster Wheeler to design new Alcon plant in Singapore

<p>Foster Wheeler's US subsidiary, Biokinetics, Inc, along with Foster Wheeler's Singapore office, have been awarded a contract by Alcon Laboratories to provide engineering and architectural services for the conceptual and basic design of its new 250,000 sq ft manufacturing facility to be located in the Tuas Biomedical Park in Singapore. </p>
Subscribe now